{"id":"W4220900778","doi":"10.1158/1538-7445.sabcs21-p1-18-03","title":"Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i>-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Fulvestrant; Rash; Internal medicine; Maculopapular rash; Letrozole; Clinical endpoint; Cohort; Oncology; Cancer; Hazard ratio; Breast cancer; Adverse effect; Confidence interval; Clinical trial; Estrogen receptor; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001011105,0.001252125,0.002087947,0.001041295,0.0008085702,0.0001029338,0.0007797254,0.0003092077,0.003574591],"category_scores_gemma":[0.0001660569,0.001045117,0.0002802589,0.002798152,0.001371632,0.001083986,0.0004149644,0.002987154,0.00002256945],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005409825,"about_ca_system_score_gemma":0.002233734,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01568749,"about_ca_topic_score_gemma":0.002611979,"domain_scores_codex":[0.9888228,0.0009497318,0.001682309,0.002271456,0.003995155,0.002278597],"domain_scores_gemma":[0.9938414,0.0004584245,0.0009774852,0.001198258,0.002494075,0.001030333],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2303482,0.007281109,0.4521327,0.001194067,0.003092885,0.0009555421,0.007437413,0.00157848,0.2682523,0.00002248564,0.004446244,0.02325862],"study_design_scores_gemma":[0.0613809,0.009856927,0.7510757,0.003261225,0.0003449872,0.00006363081,0.002751046,0.00002469051,0.1689585,0.00003725624,0.0005048951,0.001740179],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9756997,0.00176156,0.00001308913,0.0008265981,0.0002914843,0.008000292,0.01296459,0.0001994234,0.0002432572],"genre_scores_gemma":[0.990268,0.0005061963,0.0003348905,0.000230071,0.0003631974,0.005417103,0.001995559,0.0004022312,0.0004827316],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.298943,"threshold_uncertainty_score":0.999313,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02095730569695405,"score_gpt":0.3205103256317687,"score_spread":0.2995530199348146,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}